SR 56 is a California Senate resolution that proclaims September 2025 as Ovarian Cancer Awareness Month. The text compiles national statistics on incidence, mortality, stage at diagnosis and survival rates, highlights common symptoms, and urges increased awareness, preventive care, and support for survivors and caregivers.
The measure is a nonbinding legislative statement rather than a law; its practical effect is symbolic and programmatic. For public-health actors and advocacy groups, the resolution provides a state-level imprimatur they can cite when coordinating outreach, fundraising, or awareness activities during September 2025.
At a Glance
What It Does
The resolution formally designates September 2025 as Ovarian Cancer Awareness Month and records a series of "whereas" findings about incidence, mortality, stage distribution, survival, symptoms, and the burdens on families. It concludes by directing the Secretary of the Senate to transmit copies of the resolution to the author for distribution.
Who It Affects
Primary audiences are public-health agencies, nonprofit cancer advocacy organizations, clinicians who treat gynecologic cancers, and media outlets that plan health observances. The resolution does not create regulatory duties for private entities or new funding streams.
Why It Matters
Although ceremonial, the resolution aggregates authoritative statistics and a short symptom checklist that advocacy groups and health departments can reuse in outreach. It also formalizes state recognition, which can help coordinate statewide messaging and lend credibility to fundraising or awareness campaigns.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
SR 56 is a Senate resolution that does two basic things: it collects findings about ovarian cancer—numbers, survival outcomes, age distribution, common late-stage presentation, and symptom signals—and it formally proclaims September 2025 as Ovarian Cancer Awareness Month. The resolution quotes American Cancer Society estimates for 2025 and lists survival rates by stage, emphasizing that most cases are found at advanced stages and that early detection yields the best outcomes.
The text calls on women to pursue preventive care and to seek evaluation for persistent, unexplained symptoms such as bloating, pelvic or abdominal pain, eating difficulties, and urinary urgency. It frames ovarian cancer as a disease with outsized lethality relative to its share of female cancer cases and highlights the emotional, physical, and financial toll on families and communities.By design, SR 56 has no regulatory or funding language; it does not alter clinical standards, create new programs, or appropriate money.
Its operational instruction is limited and administrative: the Secretary of the Senate must transmit copies of the enrolled resolution to the author so the author can distribute them to interested parties. That transmission is the procedural mechanism that allows the resolution’s language to be shared and repurposed by advocacy groups and public-health communicators.For compliance officers or program managers at health NGOs and local public-health departments, the resolution functions as a communications tool.
Organizations can cite the state's formal recognition when seeking partners, publicity, or fundraising support, but they should not treat the resolution as creating new entitlements, reimbursement rights, or clinical guidance.
The Five Things You Need to Know
SR 56 is a nonbinding California Senate resolution that proclaims September 2025 as Ovarian Cancer Awareness Month.
The resolution cites American Cancer Society estimates for 2025 of about 20,890 new ovarian cancer diagnoses and about 12,730 deaths in the United States.
It records five-year survival rates by stage quoted in the text: 93.1% (early), 74.5% (intermediate), and 30.8% (advanced).
The bill states that 70–80% of patients are diagnosed at stage 3 or later and notes that roughly 70% of newly diagnosed women are over age 55.
The only operative direction is administrative: the Secretary of the Senate must transmit copies of the enrolled resolution to the author for distribution.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Compilation of statistics and rationale for awareness
This section assembles the factual predicates the Senate uses to justify designation: incidence and mortality estimates from the American Cancer Society, stage-specific five-year survival percentages, age distribution, and a short list of common late-presenting symptoms. Practically, these findings provide the factual basis speakers and communicators will lean on when explaining why a dedicated awareness month is necessary.
Formal designation of Ovarian Cancer Awareness Month
This provision is the operative declaration: the Legislature proclaims September 2025 as Ovarian Cancer Awareness Month. It does not create legal obligations, funding, or programmatic requirements; its force is ceremonial and persuasive, intended to support outreach and recognition.
Administrative direction to distribute the resolution
A short administrative clause directs the Secretary of the Senate to transmit copies of the enrolled resolution to the author for appropriate distribution. That clause is the only implementation step: it enables the author and interested organizations to disseminate the resolution text to stakeholders, media, and advocacy partners.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Ovarian cancer patients and survivors — the proclamation raises public visibility, validates their experiences, and can increase public sympathy which advocates can convert into support for services.
- Cancer advocacy and nonprofit organizations — the state’s formal recognition provides a citation they can use in campaigns, grant applications, and partnership outreach during September.
- Local and state public-health departments — the resolution creates a timely hook for coordinated awareness campaigns, educational events, and media outreach without needing to justify a new initiative.
- Clinical and research centers focused on gynecologic oncology — hospitals and researchers can leverage the month to promote screening research, recruitment for studies, and public education.
Who Bears the Cost
- Secretary of the Senate — minimal administrative task of transmitting copies and any incidental reproduction or distribution costs.
- Advocacy groups and public-health offices — expected to mobilize events or information campaigns tied to the proclamation, often using limited staff and volunteer resources.
- Clinicians and health systems — may see increased patient inquiries or visits prompted by heightened awareness, which can create short-term demand on scheduling and triage resources.
Key Issues
The Core Tension
The central dilemma is symbolic recognition versus concrete action: SR 56 boosts visibility and gives advocates a foothold for outreach, but it does not address the structural needs—funding, clinical capacity, or validated screening tools—that are necessary to materially improve early diagnosis and outcomes.
SR 56 is expressly ceremonial: it contains no funding, regulatory change, or statutory mandate. That limits its direct policy impact but increases its utility as a communications tool.
The resolution’s factual findings are drawn from national estimates and present a concise symptom checklist; however, those statements stop short of offering clinical guidance or recommending screening protocols, which remain matters for medical associations and regulatory bodies.
There are practical tensions around implementation. Awareness campaigns can increase demand for clinical evaluation and diagnostic services; without accompanying funding or capacity planning, heightened outreach could create access bottlenecks, particularly in underserved or rural areas.
The resolution also risks oversimplifying complex screening realities: the text recognizes that reliable population screening for ovarian cancer does not exist, yet promotes early care-seeking—a message that must be carefully framed to avoid false reassurance or unnecessary diagnostic workups.
Finally, measuring the resolution’s effectiveness is nontrivial. Proclaiming a month does not produce metrics; evaluating whether the designation improved early detection, reduced disparities, or supported survivors requires planners to set goals, allocate resources for evaluation, and coordinate across agencies and nonprofits—all steps not supplied by the resolution itself.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.